- Home
- PDM vs BCAX Comparison
PDM vs BCAX Comparison
Compare PDM & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- BCAX
- Stock Information
- Founded
- PDM 1997
- BCAX 2018
- Country
- PDM United States
- BCAX United States
- Employees
- PDM N/A
- BCAX N/A
- Industry
- PDM Building operators
- BCAX
- Sector
- PDM Real Estate
- BCAX
- Exchange
- PDM Nasdaq
- BCAX NYSE
- Market Cap
- PDM 921.9M
- BCAX 487.6M
- IPO Year
- PDM N/A
- BCAX 2024
- Fundamental
- Price
- PDM $7.55
- BCAX $10.19
- Analyst Decision
- PDM Buy
- BCAX Strong Buy
- Analyst Count
- PDM 5
- BCAX 7
- Target Price
- PDM $9.40
- BCAX $29.17
- AVG Volume (30 Days)
- PDM 900.6K
- BCAX 671.5K
- Earning Date
- PDM 07-28-2025
- BCAX 08-16-2025
- Dividend Yield
- PDM 6.63%
- BCAX N/A
- EPS Growth
- PDM N/A
- BCAX N/A
- EPS
- PDM N/A
- BCAX N/A
- Revenue
- PDM $568,472,000.00
- BCAX N/A
- Revenue This Year
- PDM $0.50
- BCAX N/A
- Revenue Next Year
- PDM N/A
- BCAX N/A
- P/E Ratio
- PDM N/A
- BCAX N/A
- Revenue Growth
- PDM N/A
- BCAX N/A
- 52 Week Low
- PDM $5.46
- BCAX $7.80
- 52 Week High
- PDM $11.12
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- PDM 59.71
- BCAX N/A
- Support Level
- PDM $7.33
- BCAX N/A
- Resistance Level
- PDM $7.72
- BCAX N/A
- Average True Range (ATR)
- PDM 0.19
- BCAX 0.00
- MACD
- PDM 0.01
- BCAX 0.00
- Stochastic Oscillator
- PDM 86.15
- BCAX 0.00
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.